A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
OSE Immunotherapeutics and HalioDx announced a collaboration to conduct a translational investigation of immune biomarkers as part of the ongoing Phase 3 clinical trial of ...